For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
The Sunday Read: ‘The Great Freight-Train Heists of the 21st Century’
On the Ballot in South Carolina: Biden’s Pitch to Black Voters
Secure the Border, Say Republicans. So Why Are They Killing a Plan to Do That?
Is the Future of Medicine Hidden in Ancient DNA?
Trump’s Voters vs. Haley’s Donors
The Failed Promise of Police Body Cameras
The Sunday Read: ‘The Whale Who Went AWOL’
The Mother Who Changed: A Story of Dementia
The Hybrid Worker Malaise
Why the G.O.P. Nomination Fight Is Now (All But) Over
The Shadowy Story of Oppenheimer and Congress
The Rules of War
The Sunday Read: ‘Podcasters Took Up Her Sister’s Murder Investigation. Then They Turned on Her’
The Fishermen Who Could End Federal Regulation as We Know It
What the Houthis Really Want
The Messy Fight Over the SAT
Trump’s Domination and the Battle for No. 2 in Iowa
The Sunday Read: ‘How an Ordinary Football Game Turns Into the Most Spectacular Thing on TV’
In Iowa, Two Friends Debate DeSantis vs. Trump
The Threat of a Wider War in the Middle East
Create your
podcast in
minutes
It is Free
Up First
Post Reports
The Journal.
The Ezra Klein Show
Today, Explained